Evolution in the indications for anti-viral therapy in chronic hepatitis B
10.3969/j.issn.1001-5256.2023.06.007
- VernacularTitle:慢性乙型肝炎抗病毒治疗适应证的变迁
- Author:
Jinjin LIU
1
;
Mengyang ZHANG
1
;
Yameng SUN
1
;
Hong YOU
1
Author Information
1. Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China
- Publication Type:Guideline Interpretation
- Keywords:
Hepatitis B, Chronic;
Anti-Viral Treatment;
Treatment Indication
- From:
Journal of Clinical Hepatology
2023;39(6):1299-1303
- CountryChina
- Language:Chinese
-
Abstract:
In order to reduce the disease burden of chronic hepatitis B (CHB) and improve the treatment rate of CHB, the indications for anti-viral therapy have been gradually expanded and simplified in guidelines for the prevention and treatment of CHB released by Chinese Medical Association from 2005 to 2022. This article elaborates on the evolution in the indications for anti-viral therapy in CHB from the five aspects of converging indications of HBeAg-positive and HBeAg-negative CHB, reduction in the treatment threshold of HBV DNA, reduction in the treatment threshold of serum alanine aminotransferase, emphasis on the risk factors for disease progression, and gradual loosening of the requirements for virological indicators in patients with liver cirrhosis.
